Jørgen Petersen

Title: Jørgen Petersen: Innovator in Monoclonal Antibody Research

Introduction

Jørgen Petersen is a prominent inventor based in Rungsted Kyst, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 15 patents to his name, Petersen's work has the potential to impact cancer treatment and immunology.

Latest Patents

Among his latest patents, Petersen has developed methods for treating cancer using human monoclonal antibodies against interleukin 8 (IL-8). These isolated human monoclonal antibodies can be produced in hybridomas, transfectomas, or non-human transgenic animals, such as transgenic mice. His patents also include pharmaceutical compositions that utilize these antibodies, along with therapeutic and diagnostic methods for their application. Another significant patent involves human monoclonal antibodies against CD25, which bind to and inhibit human CD25. Similar to his work on IL-8, these antibodies can also be produced through hybridomas, transfectomas, or transgenic animals, and include related antibody-based compositions and therapeutic methods.

Career Highlights

Petersen has worked with notable companies in the biotechnology sector, including Genmab A/S and Cormorant Pharmaceuticals AB. His experience in these organizations has allowed him to further his research and development efforts in monoclonal antibody technology.

Collaborations

Throughout his career, Jørgen Petersen has collaborated with esteemed colleagues such as Ole Baadsgaard and Jan G. J. Van De Winkel. These partnerships have contributed to the advancement of his research and the successful development of innovative therapeutic solutions.

Conclusion

Jørgen Petersen's contributions to the field of monoclonal antibodies exemplify the impact of innovation in biotechnology. His patents and collaborations highlight the importance of research in developing effective treatments for diseases such as cancer.